| P50 | author | Oliver A Cornely | Q57062280 |
| P2093 | author name string | Georg Hempel | |
| | Andreas H Groll | |
| | Peter Bader | |
| | Thomas Lehrnbecher | |
| | Carsten Müller | |
| | Fedja Farowski | |
| | Silke Gastine | |
| | Judith Ullmann-Moskovits | |
| P2860 | cites work | A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients | Q28189320 |
| | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| | Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial | Q28278518 |
| | PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. | Q33219671 |
| | Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies | Q33392206 |
| | Handling data below the limit of quantification in mixed effect models | Q33447430 |
| | Voriconazole pharmacokinetics and pharmacodynamics in children | Q33577291 |
| | Tips and traps analyzing pediatric PK data. | Q33820152 |
| | Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. | Q34138276 |
| | Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children | Q34150923 |
| | The initial 96 hours of invasive pulmonary aspergillosis: histopathology, comparative kinetics of galactomannan and (1->3) β-d-glucan and consequences of delayed antifungal therapy | Q34290097 |
| | Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation | Q34427584 |
| | Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation | Q34450423 |
| | Voriconazole monitoring in children with invasive fungal infections | Q35157940 |
| | Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients | Q35270270 |
| | Achieving target voriconazole concentrations more accurately in children and adolescents | Q35607652 |
| | Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation | Q35659502 |
| | Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults | Q36018595 |
| | Pharmacodynamics of Voriconazole in Children: Further Steps along the Path to True Individualized Therapy | Q36730105 |
| | Software for dosage individualization of voriconazole for immunocompromised patients | Q36757595 |
| | Invasive fungal infections in children | Q37562755 |
| | Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology | Q37688257 |
| | Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations | Q38738090 |
| | Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation | Q38838267 |
| | Determination of a suitable voriconazole pharmacokinetic model for personalised dosing | Q38931118 |
| | Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens | Q39652421 |
| | Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre | Q39893350 |
| | Septic shock attributed to Candida infection: importance of empiric therapy and source control | Q40026437 |
| | Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. | Q40118820 |
| | Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry | Q40337647 |
| | Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. | Q40407579 |
| | Utility of voriconazole therapeutic drug monitoring: a meta-analysis | Q40679884 |
| | Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development | Q41740968 |
| | Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study | Q44106107 |
| | Establishing best practices and guidance in population modeling: an experience with an internal population pharmacokinetic analysis guidance. | Q44108202 |
| | The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial | Q44924916 |
| | Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints. | Q47568169 |
| | Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children. | Q51067119 |
| | Automated covariate model building within NONMEM. | Q52235337 |
| | A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children | Q57730442 |
| | Pulmonary aspergillosis: early diagnosis improves survival | Q70877231 |
| | Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM | Q77296898 |
| | Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients | Q84574274 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| | voriconazole | Q412236 |
| P577 | publication date | 2017-12-21 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children | |
| P478 | volume | 62 | |